By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Elan Corp. et al. v. IntelliPharmaCeutics Corp. et al.
1:11-cv-00480; filed May 27, 2011 in the District Court of Delaware
• Plaintiffs: Elan Corp. PLC; Elan Pharma International Ltd.
• Defendants: IntelliPharmaCeutics Corp.; IntelliPharmaCeutics Ltd.; Par Pharmaceutical Inc.
Infringement of U.S. Patent Nos. 6,228,398 ("Multiparticulate Modified Release Composition," issued May 8, 2001) and 6,730,325 (same title, issued May 4, 2004), licensed to Novartis, following a Paragraph IV certification as part of IntelliPharmaceutics filing of an ANDA to manufacture a generic version of Novartis' Focalin® XR (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the complaint here.
Teva Neuroscience, Inc. et al. v. Apotex Inc. et al.
2:11-cv-03076; filed May 27, 2011 in the District Court of New Jersey
• Plaintiffs: Teva Neuroscience, Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.
• Defendants: Apotex Inc.; Apotex Corp.
Infringement of U.S. Patent No. 5,453,446 ("Use of the R-Enantiomers of N-Propargyl 1-Aminoindan Compounds for Treating Parkinson's Disease," issued September 26, 1995) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Teva's Azilect® (rasagiline mesylate, used to treat idiopathic Parkinson's disease). View the complaint here.
Celgene Corp. et al. v. Par Pharmaceutical, Inc.
2:11-cv-03094; filed May 27, 2011 in the District Court of New Jersey
• Plaintiffs: Celgene Corp.; Novartis Pharmaceuticals Corp.; Novartis Pharma AG
• Defendant: Par Pharmaceutical, Inc.
Infringement of U.S. Patent Nos. 5,908,850 ("Method of Treating Attention Deficit Disorders with d-Threo Methylphenidate," issued June 1, 1999), 6,355,656 ("Phenidate Drug Formulations Having Diminished Abuse Potential," issued March 12, 2002, with a reexamination certificate issued March 27, 2007), 6,528,530 ("Phenidate Drug Formulations Having Diminished Abuse Potential," issued March 4, 2003), 5,837,284 ("Delivery of Multiple Doses of Medications," issued November 17, 1998), 6,635,284 (same title, issued October 21, 2003), and 7,431,944 ("Delivery of Multiple Doses of Medications," issued October 7, 2008) all licensed exclusively to Novartis in certain fields of use, following a Paragraph IV certification as part of Par's filing of an ANDA to manufacture a generic version of Novartis' Focalin XR® (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the complaint here.
Abbott Laboratories et al. v. Ben Venue Laboratories Inc.
1:11-cv-00474; filed May 26, 2011 in the District Court of Delaware
• Plaintiffs: Abbott Laboratories; Wisconsin Alumni Research Foundation
• Defendant: Ben Venue Laboratories Inc.
Infringement of U.S. Patent Nos. 5,587,497 ("19-nor-Vitamin D Compounds," issued December 24, 1996), 6,136,799 ("Cosolvent Formulations," issued October 24, 2000), and 6,361,758 (same title, issued March 26, 2002,) following a Paragraph IV certification as part of Ben Venue's filing of an ANDA to manufacture a generic version of Abbott's Zemplar® (paricalcitol, used to treat secondary hyperparathyroidism in patients with kidney failure). View the complaint here.
Somaxon Pharmaceuticals Inc. v. Par Pharmaceutical Inc. et al.
1:11-cv-00476; filed May 26, 2011 in the District Court of Delaware
• Plaintiff: Somaxon Pharmaceuticals Inc.
• Defendants: Par Pharmaceutical Inc.; Par Pharmaceutical Companies Inc.
Infringement of U.S. Patent No. 6,211,229 ("Treatment of Transient and Short Term Insomnia," issued April 3, 2001) following Par's filing of an ANDA to manufacture a generic version of Somaxon's Silenor® (doxepin, used to treat insomnia). View the complaint here.
Galderma Laboratories Inc. et al. v. Impax Laboratories Inc.
1:11-cv-00477; filed May 26, 2011 in the District Court of Delaware
• Plaintiffs: Galderma Laboratories Inc.; Galderma Laboratories LP; Supernus Pharmaceuticals Inc.
• Defendant: Impax Laboratories Inc.
Infringement of U.S. Patent No. 7,749,532 ("Once Daily Formulation of Tetracyclines," issued July 6, 2010), licensed to Galderma, following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Galderma's Oracea® (doxycyline delayed release capsules, used to treat inflammatory lesions of rosacea). View the complaint here.
InSite Vision Inc. et al. v. Sandoz Inc. et al.
3:11-cv-03080; filed May 26, 2011 in the District Court of New Jersey
• Plaintiffs: InSite Vision Inc.; Inspire Pharmaceuticals, Inc.; Pfizer Inc.
• Defendants: Sandoz Inc.; Sandoz GmbH; Sandoz Industrial Products S.A.
Infringement of U.S. Patent Nos. 6,861,411 ("Method of Treating Eye Infections with Azithromycin," issued March 1, 2001), 6,159,458 ("Sustained Release Ophthalmic Compositions Containing Water Soluble Medicaments," issued December 12, 2000), 6,239,113 ("Topical Treatment or Prevention of Ocular Infections," issued May 29, 2001), 6,569,443 (same title, issued May 27, 2003), and 7,056,893 (same title, issued June 6, 2006), licensed to Inspire, following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Inspire's AzaSite® (azithromycin, used to treat bacterial conjunctivitis). View the complaint here.
Lupin Atlantis Holdings S.A. et al. v. Paddock Laboratories, Inc.
1:11-cv-03628; filed May 26, 2011 in the Southern District of New York
• Plaintiffs: Lupin Atlantis Holdings S.A.; Ethypharm S.A.
• Defendant: Paddock Laboratories, Inc.
Infringement of U.S. Patent No. 7,863,331 ("Pharmaceutical Composition Containing Fenofibrate and Method for the Preparation Thereof," issued January 4, 2011) following a Paragraph IV certification as part of Paddock's filing of an ANDA to manufacture a generic version of Lupin's Antara® (fenofibrate, used to treat hypercholesterolemia and hypertriglyceridemia). View the complaint here.
Comments